iX Biopharma Successfully Completes Pilot Bioavailability Study

iX Biopharma has successfully completed a pilot bioavailability study for PheoniX™, a product currently being developed for the treatment of male erectile dysfunction.

PheoniX™ is one of three products currently under development by the group. The product administers sildenafil via its proprietary sublingual drug delivery technology, Waferix™. The results of the pilot bioavailability study demonstrated that the sublingual wafer formulation of PheoniX™ has a similar rate and extent of drug absorption as a Viagra® tablet. The group intends to conduct a pivotal bioequivalence study for marketing authorisation, planned for the first quarter of 2016 as previously scheduled, to coincide with the upscaling of commercial production.

More From Shares Investment:

• Ken Chee: 3 Misperceptions You May Have about Investing

• SI Research: 3 Trends in S-REIT

• Dan Loeb: 5 Reasons Why You Should Short the Market